Oral citicoline combination linked to cognitive gains in prodromal dementia patients

A combined oral citicoline preparation was associated with multidomain improvements in cognitive function and mood in people with prodromal dementia, according to a two-centre observational study published in February 2026 in Nutrients. The paper provides some of the first real-world data on a citicoline-based formulation in this population. The authors say plainly that the observational design cannot establish cause and effect and that the results need confirmation in randomised controlled trials.

The study, led by neurologist Aynur Özge of the Brain Health Clinic in Mersin, Türkiye, followed 100 patients who took a daily oral supplement containing 500 mg of citicoline alongside phosphatidylserine, uridine monophosphate, and vitamins B1, B2, B6, and B12 (marketed as Ocean Cogniven by Orzax Medicine Inc., Istanbul). Fifty age-matched cognitively healthy adults were the control group. Participants came from 3,690 patients seen at two tertiary cognitive clinics. Each person was assessed at baseline and again six to nine months later with a 70-minute neuropsychological battery.

The diagnostic spread in the treatment group captures the messiness of real memory-clinic rosters: 21 percent had subjective cognitive decline, 36 percent met criteria for mild cognitive impairment, 28 percent had early-stage Alzheimer-type cognitive decline, 12 percent had moderate Alzheimer-type dementia, and 3 percent had other dementia syndromes. Within the MCI and early Alzheimer’s categories, roughly two-thirds showed an amnestic single-domain profile; the remaining third had involvement across multiple cognitive domains.

What the study found

The citicoline group improved across multiple cognitive domains over the follow-up period. Executive functions, processing speed, working memory, visual-spatial memory, and both semantic and episodic verbal fluency all registered gains at p < 0.05. Functional memory scanning, measured by the Short Blessed Test (SBST), and global cognition on the Montreal Cognitive Assessment (MoCA) also rose. Between-group differences at both time points reached p < 0.001 for most cognitive indices.

Mood followed the same direction. Depression scores fell in the citicoline group versus controls (p < 0.001). Anxiety scores dropped by a smaller but still significant margin (p = 0.018). Affective symptoms are common in prodromal dementia and confound cognitive performance measures, which makes the mood signal worth tracking alongside the cognitive one.

The effects were not spread evenly across the cohort. Age-adjusted models flagged age as a strong covariate: after adjustment, only Trail Making Test A (processing speed) and episodic fluency stayed significant. Education-stratified analyses showed that participants with less formal schooling had the largest cognitive gains, particularly in processing speed, cognitive flexibility, and episodic fluency. Those with university or postgraduate education showed more selective shifts, mainly in working memory and functional memory scanning.

“The differential patterns of change observed across age and education groups highlight the importance of individualised supportive strategies rather than uniform intervention paradigms,” the authors wrote. That lower-education participants gained the most fits the cognitive reserve model: people with fewer years of formal schooling have less buffering capacity against neurodegeneration, which may leave more room for a nutritional intervention to produce a measurable signal.

How the formulation works

Citicoline (CDP-choline) is the body’s natural precursor to phosphatidylcholine and acetylcholine. The supplement supplies choline and cytidine, raw materials the brain uses to build neuronal membranes and produce neurotransmitters. In a 2024 review in the Journal of Alzheimer’s Disease, Gareri and colleagues catalogued five mechanisms through which citicoline may act: it stabilises neuronal membranes, ramps up phospholipid synthesis, improves mitochondrial efficiency, modulates dopaminergic and cholinergic transmission, and reduces oxidative stress. A 2023 meta-analysis by Bonvicini and colleagues in Nutrients pulled together the clinical evidence and found small-to-moderate cognitive benefits in older adults with MCI and early-stage dementia, with few side effects.

The specific product tested in the Özge study, Ocean Cogniven, combines citicoline with three additional ingredients. Phosphatidylserine is a phospholipid that sits in neuronal membranes and has its own track record of small trials showing memory and attention benefits. Uridine monophosphate has been tied to synapse formation in animal models, though the jump from rodent data to human cognition is a large one. B vitamins have the strongest evidence base of the four ingredients: they are essential cofactors in mitochondrial energy metabolism and neurotransmitter synthesis, and deficiency states produce measurable cognitive deficits. The authors are upfront that the study cannot tell you which piece of this formulation is responsible for what effect. A future trial comparing the combination against citicoline alone would answer that question.

What the rest of the evidence says

The citicoline literature is larger than many supplement categories but still rests heavily on small trials. The Secades and Gareri pharmacological review from 2022 sifted through two decades of preclinical and clinical papers. Their read was that the signal is consistent across vascular cognitive impairment, MCI, and early Alzheimer’s disease, but the individual studies are small and few were preregistered. Bermejo and colleagues, writing in Neuroscience Insights in 2023, reached a similar conclusion: citicoline looks promising for memory and executive function, but the field needs larger trials with standardised outcome measures before anyone can write a confident clinical guideline.

In 2024 the European Food Safety Authority weighed in. EFSA accepted that the biology makes sense (citicoline provides precursors the brain demonstrably needs), but noted that a plausible mechanism is not the same thing as proven clinical efficacy. Their opinion did not endorse a health claim for memory.

One direct comparison exists. A 2025 meta-analysis by Sagaro and Amenta in Frontiers in Neurology pooled three RCTs that tested citicoline against choline alphoscerate, a related cholinergic precursor, in patients with vascular dementia. Choline alphoscerate came out ahead on a global clinical scale. Both compounds produced domain-specific gains. The analysis does not speak to Alzheimer’s disease, however, because the trials enrolled only vascular and multi-infarct dementia patients.

Caveats

The study design limits what can be concluded. It was observational, not randomised. The citicoline group was older at baseline and carried more cardiometabolic baggage: higher rates of hypertension, more lipid-lowering prescriptions, more hearing impairment. Controls exercised more. The statistical adjustments the authors applied reduce but do not eliminate these gaps. In a retrospective study drawn from clinic records, residual confounding is a structural feature, not something an extra covariate can fully fix.

The intervention was a combination product, not pure citicoline. The supplement contained phosphatidylserine, uridine monophosphate, and four B vitamins alongside the 500 mg of citicoline. The study cannot attribute the results to citicoline specifically. The manufacturer of Ocean Cogniven paid for statistical support and the article processing charges. The authors state the funder had no role in study design, analysis, or the decision to publish.

Two evidence gaps are worth flagging. No amyloid or tau biomarkers were collected, so the underlying pathology across the cohort is unknown. Some patients may have had Alzheimer’s pathology, others vascular contributions, still others mixed presentations. And no functional independence measures (IADL, ADL) were administered, which means there is no data on whether the cognitive test improvements translated into anything a patient or family member would notice in daily life. The neuropsychological battery was extensive, which raises the risk of false positives from multiple comparisons, though the authors argue that the consistent direction of results across related domains weighs against chance as a full explanation.

Bottom line

The Özge study is a real-world data point. It suggests a combined citicoline-based formulation may be linked to modest cognitive benefits across several domains in people at the prodromal stage of dementia. The effect sizes are in the same ballpark as what existing nutritional strategies and current Alzheimer’s drugs produce in early-stage disease, where nobody should expect dramatic reversals. The results are consistent with the broader citicoline literature but do not change the fundamental limitation of that literature: the evidence is associative, not causal. A prospective, randomised, biomarker-informed trial that tests the combination against citicoline alone and against placebo is the next logical step. Anyone thinking about taking citicoline should discuss it with their doctor.

References

1. Özge A, Bingöl A, Eyüboğlu S, et al. The real-world early neuroprotective effects of oral citicoline combination in prodromal dementia. Nutrients 18(4):595. 2026. https://doi.org/10.3390/nu18040595
2. Bonvicini M, Travaglini S, Lelli D, et al. Is citicoline effective in preventing and slowing down dementia? A systematic review and a meta-analysis. Nutrients 15(2):386. 2023. https://doi.org/10.3390/nu15020386
3. Gareri P, Cotroneo AM, Montella R, et al. Citicoline: a cholinergic precursor with a pivotal role in dementia and Alzheimer’s disease. J Alzheimer’s Dis 100:725-733. 2024. https://doi.org/10.3233/JAD-240123
4. Bermejo PE, Dorado R, Zea-Sevilla MA. Role of citicoline in patients with mild cognitive impairment. Neurosci Insights 18:26331055231152496. 2023. https://doi.org/10.1177/26331055231152496